Equities research analysts expect Nektar Therapeutics (NASDAQ:NKTR) to announce sales of $24.82 million for the current fiscal quarter, according to Zacks. Five analysts have made estimates for Nektar Therapeutics’ earnings. The lowest sales estimate is $20.08 million and the highest is $35.50 million. Nektar Therapeutics posted sales of $152.93 million during the same quarter last year, which would indicate a negative year over year growth rate of 83.8%. The business is scheduled to report its next earnings report on Tuesday, November 6th.
According to Zacks, analysts expect that Nektar Therapeutics will report full year sales of $1.18 billion for the current financial year, with estimates ranging from $1.17 billion to $1.20 billion. For the next fiscal year, analysts forecast that the firm will report sales of $457.12 million, with estimates ranging from $135.00 million to $1.18 billion. Zacks’ sales averages are an average based on a survey of research firms that cover Nektar Therapeutics.
Nektar Therapeutics (NASDAQ:NKTR) last posted its quarterly earnings data on Wednesday, August 8th. The biopharmaceutical company reported $5.33 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $5.22 by $0.11. Nektar Therapeutics had a net margin of 65.69% and a return on equity of 174.70%. The firm had revenue of $1.09 billion during the quarter, compared to analyst estimates of $1.03 billion. During the same quarter last year, the business posted ($0.39) EPS. The company’s revenue for the quarter was up 3043.7% on a year-over-year basis.
NKTR has been the subject of a number of research reports. ValuEngine raised shares of Nektar Therapeutics from a “hold” rating to a “buy” rating in a research report on Tuesday, August 28th. Piper Jaffray Companies set a $125.00 target price on shares of Nektar Therapeutics and gave the company a “buy” rating in a research report on Wednesday, July 25th. BidaskClub downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, September 18th. Zacks Investment Research downgraded shares of Nektar Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday. Finally, William Blair reissued an “outperform” rating on shares of Nektar Therapeutics in a research report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and ten have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $82.91.
Shares of Nektar Therapeutics stock traded up $1.01 on Wednesday, reaching $48.91. 2,001,546 shares of the company traded hands, compared to its average volume of 3,167,571. Nektar Therapeutics has a 52 week low of $22.75 and a 52 week high of $111.36. The company has a market capitalization of $10.51 billion, a P/E ratio of -88.93 and a beta of 2.39. The company has a quick ratio of 19.55, a current ratio of 19.67 and a debt-to-equity ratio of 0.13.
In related news, Director Jeffrey Robert Ajer sold 6,750 shares of the firm’s stock in a transaction that occurred on Thursday, September 20th. The shares were sold at an average price of $56.76, for a total value of $383,130.00. Following the completion of the transaction, the director now directly owns 15,750 shares of the company’s stock, valued at approximately $893,970. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Dennis L. Winger sold 30,000 shares of the firm’s stock in a transaction that occurred on Tuesday, August 21st. The stock was sold at an average price of $59.96, for a total transaction of $1,798,800.00. Following the completion of the transaction, the director now directly owns 57,750 shares of the company’s stock, valued at $3,462,690. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 96,000 shares of company stock valued at $5,825,680. 4.31% of the stock is owned by insiders.
A number of large investors have recently made changes to their positions in NKTR. Asset Management One Co. Ltd. purchased a new position in Nektar Therapeutics in the 1st quarter worth $110,000. We Are One Seven LLC purchased a new position in Nektar Therapeutics in the 1st quarter worth $118,000. Suntrust Banks Inc. purchased a new position in Nektar Therapeutics in the 1st quarter worth $264,000. Livforsakringsbolaget Skandia Omsesidigt purchased a new position in Nektar Therapeutics in the 2nd quarter worth $137,000. Finally, Flagship Harbor Advisors LLC purchased a new position in Nektar Therapeutics in the 2nd quarter worth $142,000. 92.20% of the stock is owned by hedge funds and other institutional investors.
About Nektar Therapeutics
Nektar Therapeutics, a research-based biopharmaceutical company, discovers and develops drug candidates for cancer, auto-immune disease, and chronic pain in the United States. The company offers ONZEALD, a topoisomerase I inhibitor that is in Phase III clinical trial for advanced metastatic breast cancer in patients with brain metastases; NKTR-181, an orally-available mu-opioid analgesic molecule, which is in Phase III clinical trial for moderate to severe chronic pain; NKTR-214, a cytokine immunostimulatory therapy that is in Phase I/II to treat cancer; NKTR-358, which is in Phase I to treat autoimmune diseases; and NKTR-262 for solid tumors, as well as NKTR-255 that is under research/preclinical stage for immuno-oncology.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.